Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA-02: Palazestrant + ribociclib versus letrozole + ribociclib in first-line ER-positive, HER2-negative advanced breast cancer
MOH_2026-04-12_015760Phase 3Not yet recruiting
- Sponsor
- Olema Oncology
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of palazestrant, sponsored by Olema Oncology. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
palazestrant
Beyond the preview
Go deeper on MOH_2026-04-12_015760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-12_015760.